Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
29.94 ^USD	-1.84%		-1.84%	+10.68%

06-13	Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors	CI
06-11	Transcript : Guardant Health, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM

Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 10:00 pm

Guardant Health, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 168.49 million compared to USD 128.71 million a year ago. Net loss was USD 114.99 million compared to USD 133.53 million a year ago.

Basic loss per share from continuing operations was USD 0.94 compared to USD 1.3 a year ago.

Latest news about Guardant Health, Inc.

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors	06-13	CI
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM	06-11
Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	06-04	MT
Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer	06-04	CI
Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	06-03	MT
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading	05-24	MT
Guardant Health's Shares Rise as Colorectal Cancer Detection Test Gets FDA Panel Recommendation	05-24	MT
Sector Update: Health Care Stocks Advance Pre-Bell Friday	05-24	MT
Sector Update: Health Care	05-24	MT
Wall Street Rebounds From Thursday's Slide, Driving Narrow Gains for US Equity Futures Pre-Bell	05-24	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Hope for September Interest Rate Cuts	05-24	MT
Top Premarket Gainers	05-24	MT
Guardant Health Says Colorectal Cancer Detection Test Receives FDA Panel Recommendation	05-24	MT
Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield? Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option	05-24	CI
Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test	05-23	DJ
U.S. FDA advisers back approval for Guardant's cancer test	05-23	RE
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test	05-23	MT
Guardant Health Gets EU Certification for Blood-Based Test for Comprehensive Genomic Profiling of Solid Cancers	05-21	MT
Guardant Health, Inc. Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications	05-21	CI
Transcript : Guardant Health, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	05-15
Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised	05-10	MT
Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (GH) GUARDANT HEALTH Reports Q1 Revenue $168.5M, vs. Street Est of $150.1M	05-09	MT
Transcript : Guardant Health, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024	05-09	CI

Chart Guardant Health, Inc.

Duration

Period

More charts

Company Profile

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Guardant Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.94 USD

Average target price

37.53 USD

Spread / Average Target

+25.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
GUARDANT HEALTH, INC.	+10.68%	3.66B
EXACT SCIENCES CORPORATION	-43.34%	7.74B
IOVANCE BIOTHERAPEUTICS, INC.	-1.60%	2.24B
BGI GENOMICS CO., LTD.	-22.96%	1.98B
VERACYTE, INC.	-22.17%	1.64B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+5.19%	915M
CAREDX, INC	+17.25%	733M
SEEGENE, INC.	-6.99%	710M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-37.14%	454M
CURIOX BIOSYSTEMS CO., LTD	-2.29%	287M

Bio Diagnostics & Testing